Publicacións en colaboración con investigadores/as de Hospital Severo Ochoa (10)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  2. Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV

    Biochemical Pharmacology, Vol. 229

  3. Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib

    Frontiers in Pharmacology, Vol. 15

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU

    Frontiers in Immunology, Vol. 12

  2. Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity

    Frontiers in Immunology, Vol. 12

  3. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

    Biochemical Pharmacology, Vol. 192

2017

  1. PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase

    PLoS ONE, Vol. 12, Núm. 7

2015

  1. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

    Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002

2014

  1. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211